National Advertising Division Finds Certain Claims for Early Defense Dietary Supplement Supported; Recommends Others be Modified or Discontinued

New York, NY – June 6, 2024 – In a challenge brought by MacuHealth LP, BBB National Programs’ National Advertising Division determined that Vision Elements, Inc. substantiated shelf-life stability and safety claims for its Early Defense dietary supplement.  

However, the National Advertising Division (NAD) recommended that other challenged claims be discontinued or modified.

Vision Element’s Early Defense product contains a triple carotenoid formula as its active ingredient, along with other excipients, and is marketed to support healthy eyesight.

Published Studies Claim

The National Advertising Division (NAD) determined that one reasonable takeaway from Vision Element’s claim “Science-Driven Formulas developed from peer-reviewed, published studies” is that Early Defense’s formula is the same as that tested in peer reviewed published studies.

Since there was no evidence in the record that Early Defense’s formula has been the subject of peer-reviewed published studies, NAD recommended the claim be discontinued. NAD noted that nothing in its decision prevents Vision Elements from claiming that the ingredients were developed from peer-reviewed published studies provided that the claim is properly substantiated. 

Performance Claims

The National Advertising Division (NAD) concluded that there was no evidence to support the challenged claim that Early Defense “helps maintain healthy eyesight and visual performance” because the studies and meta-analysis relied on by the advertiser were not conducted on the Early Defense product. Therefore, NAD recommended the claim be discontinued but noted that nothing in its decision prevents Vision Elements from tailoring its claims to the benefits specific ingredients in Early Defense can provide, as long as the claims are substantiated by competent and reliable scientific evidence. 

NAD also recommended that Vision Elements remove the patient testimonial from its website stating, “I have been taking Early Defense capsules since January… I have great clarity, contrast and colour tone” due to a lack of evidence in the record.

Bioavailability and Absorption Claims

MacuHealth challenged the claim “Liquid-Filled Hard Capsules: Advanced encapsulation technology helps protect the carotenoids through shelf-life and aid absorption.”

The National Advertising Division (NAD) found Vision Element’s evidence shows that liquid-filled hard capsules are generally accepted by scientists to help maintain a product’s shelf-life stability without impacting absorption. Therefore, NAD determined that Vision Elements has a reasonable basis for the claim “Liquid-Filled Hard Capsules: Advanced encapsulation technology helps protect the carotenoids through shelf-life” but recommended it modify the portion of the claim that the technology will “aid absorption” to better fit the evidence.  

NAD concluded the claim that “Vision Elements liquid-filled capsules naturally enhance carotenoid absorption and bioavailability with a combination of olive oil and non-GMO sunflower lecithin” is not supported by the record and recommended it be discontinued.

Shelf-Life Stability & Safety Claims

The National Advertising Division (NAD) found that testing of the Early Defense product for harmful substances, the FDA’s Generally Recognized As Safe (GRAS) information on individual ingredients and product testing on Early Defense for potency, even after the product is on shelves, is enough to constitute competent and reliable scientific evidence that multiple tests are conducted to assess for safety and potency.

Therefore, NAD found that Vision Elements substantiated claims that:

  • “Purity content and shelf-life stability are proven over and again through extensive ongoing quality control testing”; and
  • “Multiple tests are performed throughout the production process to ensure safety and potency.”

 

In its advertiser statement, Vision Elements stated that it agrees to comply with NAD’s recommendations although it respectfully disagrees with certain of NAD’s conclusions.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than a dozen globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create a fairer playing field for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. The National Advertising Division reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.

Contact Information:
Name: Jennie Rosenberg
Email: jrosenberg@bbbnp.org
Job Title: Media Relations

Following National Advertising Division Challenge, Summus Medical Laser Voluntarily Discontinues Certain Claims

New York, NY – June 4, 2024 – Following a BBB National Programs’ National Advertising Division challenge brought by competitor Multi Radiance Medical, Summus Medical Laser voluntarily discontinued certain claims for its Medical Laser product.

Multi Radiance Medical challenged claims that it argued were outside the indications allowed by the Food and Drug Administration (FDA) for devices registered under product code ILY for temporary relief of minor muscle and joint pain, arthritis, and muscle spasms, relieving stiffness, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation where heat is indicated.

In response to the challenge, Summus stated that it is permanently discontinuing the challenged claims. Therefore, the National Advertising Division (NAD) did not review the claims on their merits and will treat the claims, for compliance purposes, as though NAD recommended they be discontinued.

In its advertiser statement, Summus stated that it agrees to comply with NAD’s recommendations and appreciates the opportunity to participate in the self-regulatory process.

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. This press release shall not be used for advertising or promotional purposes.

About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than a dozen globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create a fairer playing field for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit bbbprograms.org.

About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and leveling the playing field for business.  

Contact Information

Name: Jennie Rosenberg
Email: jrosenberg@bbbnp.org
Job Title: Media Relations

LexisNexis to Acquire Document Drafting Tech Provider Henchman

Acquisition will combine Henchman’s Document Management System data enrichment with trusted LexisNexis drafting guidance content to deliver personalized generative AI experience

NEW YORK, June 3, 2024LexisNexis Legal & Professional®, a leading global provider of information and analytics, today announced it has agreed to acquire Henchman, a legal tech company that enriches data from Document Management Systems (DMS) for faster document drafting. Henchman is a Belgium-based company, founded in 2020, with 170+ legal and corporate customers globally including top U.S. and European law firms and companies.

By acquiring Henchman, LexisNexis will deliver personalized generative AI solutions to customers around the world. Henchman core product functionality will be available to existing and new customers. LexisNexis has immediate plans to utilize Henchman’s technology with its proprietary Retrieval Augmented Generation 2.0 (RAG 2.0) platform in its flagship Lexis+ AI solution, enabling the use of trusted customer data as grounding data for generative AI drafting. Henchman’s capabilities will also be added to Lexis® Create, the Microsoft 365 add-in solution that enables point-of-workflow integration for generative AI drafting in Microsoft Word, Outlook, Teams and Copilot.

Henchman is used by leading law firms and corporations to enrich internal work product, creating a layer of intelligence on contract databases to accelerate drafting tasks.

Henchman interacts with the DMS of a law firm or corporation, indexing the organization’s precedent documents at the clause level, making the data available for contract insights and drafting. Its technology works with legal-specific DMS providers and general enterprise content management systems and is language agnostic. Henchman’s technology incorporates security and conflict settings that mirror document permissions within the DMS, preserving firm confidentiality and privacy requirements. These benefits are available to customers in days, not months, from deployment of the technology.

Advanced technology processes allow a customer to quickly find key insights from internal data repositories. LexisNexis will incorporate this enhanced document enrichment capability to deliver new generative AI drafting solutions.

“This is an exciting moment for our customers and the LexisNexis and Henchman teams,” said Mike Walsh, CEO, LexisNexis Legal & Professional. “We’re continuously engaging with customers to determine where AI can deliver the most value. Now, we’ll be able to address one of our legal customers’ top requests – to have searchable internal firm data, combined with our current drafting and AI offerings, allowing legal professionals to rapidly extract language and insights, and generate higher quality work using both internal data and LexisNexis solutions together.”

Henchman Co-Founder Gilles Mattelin added, “We see this union with LexisNexis as an extension of our drafting vision to proactively surface valuable and strategic insights for customers – delivering a center of knowledge to legal teams. We believe the combination of our teams and tech will empower customers to make informed decisions faster, generate outstanding work, and drive economic value for their organizations.”

Closing of the transaction is subject to customary regulatory consents and is expected early in the second half of 2024. The terms of the transaction have not been disclosed.

LexisNexis is responsibly developing legal AI solutions with human oversight. LexisNexis, part of RELX, follows the RELX Responsible AI Principles, considering the real-world impact of its solutions on people and taking action to prevent the creation or reinforcement of unfair bias.

Lexis+ AI delivers trusted results with state-of-the-art encryption and privacy technology to keep data secure. Using an extensively enhanced LexisNexis proprietary RAG 2.0 platform, Lexis+ AI responses are grounded in the world’s largest repository of up-to-date legal content which ensures the highest-quality answer with the most up-to-date validated citation references. Uploaded documents are always purged at the end of each session and users can easily manage or delete their prompt conversation history. The solution is continually improving with hundreds of thousands of rated answer samples by LexisNexis legal subject matter experts used for model tuning. LexisNexis employs over 2,000 technologists, data scientists, and subject matter experts to develop, test, and validate its solutions and deliver comprehensive, authoritative information.

For more information on Lexis+ AI and our generative AI resources for legal professionals, visit www.lexisnexis.com/ai.

About LexisNexis Legal & Professional
LexisNexis® Legal & Professional provides legal, regulatory, and business information and analytics that help customers increase their productivity, improve decision-making, achieve better outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis® and Nexis® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 11,800 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
 
Media Contact
Dana Greenstein
Director of Communications, North America & UK
LexisNexis Legal & Professional
212-448-2163
dana.greenstein@lexisnexis.com